Abstract
Two-year PSA outcomes after cesium prostate brachytherapy
Journal of clinical oncology, v 29(7_suppl), pp 92-92
01 Mar 2011
Abstract
Abstract only
92
Background: Given the long natural history of prostate cancer, long term follow up is needed to definitively know the efficacy of a new treatment, in this case
131
Cs brachytherapy. However, it is also important to report on short term outcomes to ensure that this treatment is on course to provide equivalent outcomes as compared to existing treatment options. This reports two year PSA outcomes in men undergoing prostate brachytherapy with cesium 131 at a single institution.
Methods: All patients who underwent prostate brachytherapy with
131
Cs and had at least 24 months of follow up were included in this study. Results are reported for the total cohort and stratified by risk group as well as treatment received (monotherapy, combination therapy, or trimodal therapy). The Phoenix definition was used to define biochemical disease free survival (bDFS). Outcomes were analyzed using descriptive statistics.
Results: 115 patients underwent prostate brachytherapy with
131
Cs and had at least 24 months of follow up. Fifty two (45.2%) patients were classified as low risk, 52 (45.2%) were intermediate risk, and 11 (9.6%) were high risk. Eighty one patients were treated with prostate brachytherapy as monotherapy, including six patients who received androgen-deprivation therapy (ADT) in combination with their brachytherapy. Twenty five patients received combination therapy, and 9 patients received trimodal therapy. Specifics of bDFS rates and PSA data are reported in the table. Of the 115 patients four had biochemical recurrence. Two patients died during the study period, both due to causes other than prostate cancer, and one patient was unwilling to obtain a PSA at the 24 month follow up time point.
Conclusions: The first 115 patients who have undergone prostate brachytherapy with
131
Cs at our institution have a bDFS rate of 96.4% 24 months after their procedure. With the very important caveat that only short term results are reported,
131
Cs appears to be on course to achieve results comparable to those achieved with iodine 125 (
125
I) and palladium 103 (
103
Pd).
[Table: see text]
No significant financial relationships to disclose.
Metrics
2 Record Views
Details
- Title
- Two-year PSA outcomes after cesium prostate brachytherapy
- Creators
- R. SmithB. L. Jacobs - University of Pittsburgh Medical CenterS. Beriwal - University of Pittsburgh Medical CenterR. M. Benoit - University of Pittsburgh Medical Center
- Publication Details
- Journal of clinical oncology, v 29(7_suppl), pp 92-92
- Publisher
- AMER SOC CLINICAL ONCOLOGY; ALEXANDRIA
- Number of pages
- 1
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000208880700093
- Other Identifier
- 991021897387604721
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology